Brolucizumab-Dbll vs MW02

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Age-Related Macular Degeneration

Shared mechanism: VEGF-A · full Age-Related Macular Degeneration pipeline

Brolucizumab-Dbll

Marketed by Novartis and partners

Approved in Age-Related Macular Degenerationantibody fragment (scFv)
Weak signal

NCT05672979 · Phase 3 · status unknown

This is a single-arm, unblinded study with no placebo or active comparator, so it cannot establish how much of any visual acuity change is attributable to brolucizumab itself. Results are not yet available.

No aligned efficacy figure on record for this race.

MW02

Developed by Mabwell Bioscience and partners

Phase 2/3 in Age-Related Macular Degenerationmonoclonal antibody
Partial signal

NCT05297292 · Phase 2/3 · status unknown

The seamless Phase 2/3 trial randomized 476 patients with wet AMD to MW02 or ranibizumab under double masking. The sponsor reports that the 1.5 mg dose was non-inferior to ranibizumab on best-corrected visual acuity at week 52; the registry has no posted results.

Caveat: this result is taken from a company announcement, not from the trial registry or a peer-reviewed publication. Treat it as the sponsor's own statement.

No aligned efficacy figure on record for this race.

Results for Age-Related Macular Degeneration

There are not yet structured results for two selected drugs in this indication. Available results are listed below instead of an empty comparison table.

Brolucizumab-Dbll: registry results are on file for Age-Related Macular Degeneration, but their comparison mappings are not yet available.

MW02: no structured comparison results are available for Age-Related Macular Degeneration.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Brolucizumab-Dbll's landscape · MW02's landscape